Pinnacle Conversation | Advancements in the Diagnosis and Treatment of Metabolism-Related Fatty Liver Disease: Discussing New Developments, Sharing Experiences from Singapore and the United States, and Addressing Global Progress

Pinnacle Conversation | Advancements in the Diagnosis and Treatment of Metabolism-Related Fatty Liver Disease: Discussing New Developments, Sharing Experiences from Singapore and the United States, and Addressing Global Progress

2024.01.24
Non-alcoholic fatty liver disease (NAFLD)/metabolic-associated fatty liver disease (MAFLD) is on the rise globally and has become the leading cause of chronic liver disease in China, posing a significant threat to public health. Establishing diagnostic models based on risk factors to assist clinical diagnosis and classification, or developing non-invasive assessment methods, is an important prerequisite for identifying more patients and effectively intervening in the disease process.
EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis

EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis

2024.01.18
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023 have brought forth a splendid academic gathering for the global hepatology community. The Hepatology Digest reporting team had the privilege of interviewing Doctor Thomas Berg, EASL Secretary-General and Head of the Hepatology Department at Leipzig University Hospital. He shared with us the highlights of this conference, his perspective on significant research developments, thoughts on the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD), and insights into the future research directions for fatty liver and hepatitis B.

CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

2024.01.10
Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these conditions is beneficial for reducing the burden of disease. To support the development of diabetes and liver disease co-management in China, this publication Hepatology Digest, in collaboration with the co-management of diabetes-liver diseases strategy, (CDL), presents the CDL Literature Monthly Review column. Each month, we share research literature related to the mechanisms and therapeutic advances in diabetes combined with liver diseases. We invite experts in the field to comment on the literature, hoping to provide insights and assistance for professionals, researchers, and frontline medical workers engaged in scientific research and clinical diagnosis and treatment.
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

2024.01.03
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress Dr. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve antiviral treatment of hepatitis B and C. Dr. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection. In addition, Dr Wei is involved in Kidney Disease Improving Global Outcome to develop a Guideline for HCV Infection, Diagnosis, Prevention and Management in Kidney Disease and contributes to APASL for hepatitis C guideline.
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

2024.01.03
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu University conducted research on the impact of NAFLD, as confirmed by liver histopathology, and pathological changes on individuals with chronic HBV infection. The latest research findings were selected for presentation at the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023
AASLD Interview | Professor Vincent Wai-Sun Wong: Global Differences and New Advances in the Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

AASLD Interview | Professor Vincent Wai-Sun Wong: Global Differences and New Advances in the Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

2023.12.22
In his research, Vincent Wai-Sun Wong performs multidisciplinary study on Steatohepatitis and Fatty liver. Fatty liver is frequently linked to Disease in his study. His studies link Steatohepatitis with Disease. His Gastroenterology study frequently links to adjacent areas such as Transient elastography. Transient elastography and Biopsy are commonly linked in his work. He integrates Biopsy and Fibrosis in his studies. Vincent Wai-Sun Wong conducts interdisciplinary study in the fields of Fibrosis and Inflammation through his research. His work blends Inflammation and Liver disease studies together. In his study, he carries out multidisciplinary Liver disease and Cirrhosis research.
AASLD 2023丨Landmark Chinese Study on NASH Treatment Presented at AASLD

AASLD 2023丨Landmark Chinese Study on NASH Treatment Presented at AASLD

2023.12.22
On November 11, 2023, at the American Association for the Study of Liver Diseases annual meeting (AASLD 2023), the results of China's first international registered randomized controlled trial (RCT) evaluating therapeutic efficacy through liver histology, known as the VENS study, were showcased in poster format. This presentation garnered significant attention and discussions from international experts in liver diseases. The conference brought together leading global experts in clinical hepatology, liver transplantation, and hepatobiliary surgery to advance clinical research and practices, providing optimal treatment guidance for liver and biliary disease patients.
EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

2023.10.24
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023 have brought forth a splendid academic gathering for the global hepatology community. The Hepatology Digest reporting team had the privilege of interviewing Doctor Thomas Berg, EASL Secretary-General and Head of the Hepatology Department at Leipzig University Hospital. He shared with us the highlights of this conference, his perspective on significant research developments, thoughts on the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD), and insights into the future research directions for fatty liver and hepatitis B.
New Insights from EASL: The Role of Lifestyle Interventions in Preventing and Treating NAFLD/NASH in Children and Adults

New Insights from EASL: The Role of Lifestyle Interventions in Preventing and Treating NAFLD/NASH in Children and Adults

2023.10.23
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease globally and is independently associated with an increased risk of Type 2 Diabetes (T2DM) and cardiovascular diseases. Approximately one-third of the global population is currently facing the health threat posed by NAFLD, yet it appears that healthcare systems are not giving it enough attention. On the first day of the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Elisabetta Bugianesi from the Department of Digestive Internal Medicine at the University of Turin, Italy, urged the public to take NAFLD seriously. She provided a detailed overview of lifestyle interventions as a key means of preventing and treating NAFLD, sharing the latest research evidence, guideline recommendations, and future strategies. Hepatology Digest has compiled this report for the benefit of its readers.